Patient Voice Missing In Asthma Drug Safety Debate – FDA’s Jenkins
Executive Summary
When a post-marketing safety signal arises, patients’ perspective of benefit is often drowned out by consumer advocates’ worries about a drug’s risks, the Office of New Drugs director says.